FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208698849> ?p ?o ?g. }

• W3208698849 endingPage "175883592110524" @default.
• W3208698849 startingPage "175883592110524" @default.
• W3208698849 abstract "Background: The objective of this study was to construct a risk classification system integrating cell-free Epstein-Barr virus (cfEBV) DNA with T- and N- categories for better prognostication in nasopharyngeal carcinoma (NPC). Methods: Clinical records of 10,149 biopsy-proven, non-metastatic NPC were identified from two cancer centers; this comprised a training ( N = 9,259) and two validation cohorts ( N = 890; including one randomized controlled phase 3 trial cohort). Adjusted hazard ratio (AHR) method using a two-tiered stratification by cfEBV DNA and TN-categories was applied to generate the risk model. Primary clinical endpoint was overall survival (OS). Performances of the models were compared against American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) 8th edition TNM-stage classification and two published recursive partitioning analysis (RPA) models, and were validated in the validation cohorts. Results: We chose a cfEBV DNA cutoff of ⩾2,000 copies for optimal risk discretization of OS, disease-free survival (DFS) and distant metastasis-free survival (DMFS) in the training cohort. AHR modeling method divided NPC into six risk groups with significantly disparate survival ( p < 0.001 for all): AHR1, T1N0; AHR2A, T1N1/T2-3N0 cfEBV DNA < 2,000 (EBV low ); AHR2B, T1N1/T2-3N0 cfEBV DNA ⩾ 2,000 (EBV high ) and T1-2N2/T2-3N1 EBV low ; AHR3, T1-2N2/T2-3N1 EBV high and T3N2/T4N0 EBV low ; AHR4, T3N2/T4 N0-1 EBV high and T1-3N3/T4N1-3 EBV low ; AHR5, T1-3N3/T4 N2-3 EBV high . Our AHR model outperformed the published RPA models and TNM stage with better hazard consistency (1.35 versus 3.98–12.67), hazard discrimination (5.29 versus 6.69–13.35), explained variation (0.248 versus 0.164–0.225), balance (0.385 versus 0.438–0.749) and C-index (0.707 versus 0.662–0.700). In addition, our AHR model was superior to the TNM stage for risk stratification of OS in two validation cohorts ( p < 0.001 for both). Conclusion: Herein, we developed and validated a risk classification system that combines the AJCC/UICC 8th edition TN-stage classification and cfEBV DNA for non-metastatic NPC. Our new clinicomolecular model provides improved OS prediction over the current staging system." @default.
• W3208698849 created "2021-11-08" @default.
• W3208698849 creator A5005486813 @default.
• W3208698849 creator A5007574102 @default.
• W3208698849 creator A5008644842 @default.
• W3208698849 creator A5021332443 @default.
• W3208698849 creator A5024789285 @default.
• W3208698849 creator A5026936543 @default.
• W3208698849 creator A5032164924 @default.
• W3208698849 creator A5033222360 @default.
• W3208698849 creator A5036423536 @default.
• W3208698849 creator A5049410535 @default.
• W3208698849 creator A5055912468 @default.
• W3208698849 creator A5075699837 @default.
• W3208698849 creator A5076417896 @default.
• W3208698849 creator A5078925966 @default.
• W3208698849 creator A5086855764 @default.
• W3208698849 date "2021-01-01" @default.
• W3208698849 modified "2023-10-12" @default.
• W3208698849 title "Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases" @default.
• W3208698849 cites W1570622790 @default.
• W3208698849 cites W1639620410 @default.
• W3208698849 cites W1968017437 @default.
• W3208698849 cites W1968675377 @default.
• W3208698849 cites W2023907325 @default.
• W3208698849 cites W2024847643 @default.
• W3208698849 cites W2072587322 @default.
• W3208698849 cites W2117140527 @default.
• W3208698849 cites W2138066012 @default.
• W3208698849 cites W2161043223 @default.
• W3208698849 cites W2174306046 @default.
• W3208698849 cites W2186378789 @default.
• W3208698849 cites W2193856897 @default.
• W3208698849 cites W2462540433 @default.
• W3208698849 cites W2526747727 @default.
• W3208698849 cites W2567987817 @default.
• W3208698849 cites W2576208023 @default.
• W3208698849 cites W2742681205 @default.
• W3208698849 cites W2787995167 @default.
• W3208698849 cites W2891991146 @default.
• W3208698849 cites W2897902933 @default.
• W3208698849 cites W2947165726 @default.
• W3208698849 cites W2972228663 @default.
• W3208698849 cites W3118937854 @default.
• W3208698849 cites W4210983491 @default.
• W3208698849 doi "https://doi.org/10.1177/17588359211052417" @default.
• W3208698849 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8554575" @default.
• W3208698849 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34721672" @default.
• W3208698849 hasPublicationYear "2021" @default.
• W3208698849 type Work @default.
• W3208698849 sameAs 3208698849 @default.
• W3208698849 citedByCount "8" @default.
• W3208698849 countsByYear W32086988492022 @default.
• W3208698849 countsByYear W32086988492023 @default.
• W3208698849 crossrefType "journal-article" @default.
• W3208698849 hasAuthorship W3208698849A5005486813 @default.
• W3208698849 hasAuthorship W3208698849A5007574102 @default.
• W3208698849 hasAuthorship W3208698849A5008644842 @default.
• W3208698849 hasAuthorship W3208698849A5021332443 @default.
• W3208698849 hasAuthorship W3208698849A5024789285 @default.
• W3208698849 hasAuthorship W3208698849A5026936543 @default.
• W3208698849 hasAuthorship W3208698849A5032164924 @default.
• W3208698849 hasAuthorship W3208698849A5033222360 @default.
• W3208698849 hasAuthorship W3208698849A5036423536 @default.
• W3208698849 hasAuthorship W3208698849A5049410535 @default.
• W3208698849 hasAuthorship W3208698849A5055912468 @default.
• W3208698849 hasAuthorship W3208698849A5075699837 @default.
• W3208698849 hasAuthorship W3208698849A5076417896 @default.
• W3208698849 hasAuthorship W3208698849A5078925966 @default.
• W3208698849 hasAuthorship W3208698849A5086855764 @default.
• W3208698849 hasBestOaLocation W32086988491 @default.
• W3208698849 hasConcept C126322002 @default.
• W3208698849 hasConcept C143998085 @default.
• W3208698849 hasConcept C146357865 @default.
• W3208698849 hasConcept C151730666 @default.
• W3208698849 hasConcept C203014093 @default.
• W3208698849 hasConcept C207103383 @default.
• W3208698849 hasConcept C2778997737 @default.
• W3208698849 hasConcept C44249647 @default.
• W3208698849 hasConcept C50382708 @default.
• W3208698849 hasConcept C509974204 @default.
• W3208698849 hasConcept C71924100 @default.
• W3208698849 hasConcept C72563966 @default.
• W3208698849 hasConcept C86803240 @default.
• W3208698849 hasConceptScore W3208698849C126322002 @default.
• W3208698849 hasConceptScore W3208698849C143998085 @default.
• W3208698849 hasConceptScore W3208698849C146357865 @default.
• W3208698849 hasConceptScore W3208698849C151730666 @default.
• W3208698849 hasConceptScore W3208698849C203014093 @default.
• W3208698849 hasConceptScore W3208698849C207103383 @default.
• W3208698849 hasConceptScore W3208698849C2778997737 @default.
• W3208698849 hasConceptScore W3208698849C44249647 @default.
• W3208698849 hasConceptScore W3208698849C50382708 @default.
• W3208698849 hasConceptScore W3208698849C509974204 @default.
• W3208698849 hasConceptScore W3208698849C71924100 @default.
• W3208698849 hasConceptScore W3208698849C72563966 @default.
• W3208698849 hasConceptScore W3208698849C86803240 @default.
• W3208698849 hasFunder F4320321001 @default.

• next